Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 15/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 7/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16506775 | 0.88 | MAPT (0.47) | HTR6RXFP1MAPT | |
| SCHEMBL16507615 | 0.86 | HTR6 (0.43) | HTR6RXFP1POLBMAPT | |
| SCHEMBL15285278 | 0.86 | HTR6 (0.59) | HTR6RXFP1POLBMAPTTP53 | |
| SCHEMBL16506885 | 0.86 | THRB (0.56) | HTR6RXFP1MAPTTP53 | |
| SCHEMBL16507618 | 0.85 | HTR6 (0.46) | HTR6RXFP1POLBMAPTTP53 | |
| SCHEMBL16507524 | 0.85 | HTR6 (0.42) | HTR6RXFP1POLBMAPTTP53 | |
| SCHEMBL16507185 | 0.81 | HTR6 (0.42) | HTR6RXFP1MAPTTP53 | |
| SCHEMBL15287958 | 0.68 | MAPT (0.84) | HTR6RXFP1POLBMAPTTP53 | |
| SCHEMBL15287955 | 0.68 | HTR6 (0.58) | HTR6RXFP1POLBMAPTTP53 | |
| SCHEMBL15285549 | 0.67 | HTR6 (1.00) | HTR6RXFP1POLBMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9303042-B2 | Triazolothienopyrimidine compound inhibitors of urea transporters and methods of using inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150057274-A1 | TRIAZOLOTHIENOPYRIMIDINE COMPOUND INHIBITORS OF UREA TRANSPORTERS AND METHODS OF USING INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057274-A1 | TRIAZOLOTHIENOPYRIMIDINE COMPOUND INHIBITORS OF UREA TRANSPORTERS AND METHODS OF USING INHIBITORS | SLC14A1, SLC29A2, SLC29A1 | HTR6 3397/4885RXFP1 1785/4885POLB 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.